India-EU FTA to boost pharma, chemicals trade, Indian medical professionals' credentials to gain acceptance

India-EU FTA to boost pharma, chemicals trade, Indian medical professionals' credentials to gain acceptance

• India and EU finalize FTA, cut tariffs on chemicals, pharma, medical devices
• Indian doctors can now practice in the EU through credential recognition.
• EU imports from India remain subject to strict health and product safety rules

Did our AI summary help?

The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.

Beyond goods, the FTA formalized a "shared healthcare ecosystem" by addressing professional mobility. Indian-trained medical professionals will gain new pathways to practice in the EU through the formal recognition of their credentials, enabling movement of medical expertise across borders, allowing Indian talent to integrate directly into European healthcare systems, which are facing chronic talent shortage.

India and the European Union (EU) on Tuesday finalized a landmark free trade agreement (FTA), agreeing to eliminate or reduce tariffs in many sectors including pharmaceuticals, chemicals, and medical devices.

Under the new framework, Indian tariffs on EU pharmaceutical exports currently at 11 percent and chemicals currently up to 22% will drop to 0 percent for almost all products. Similarly, 90 percent of medical and surgical equipment will see tariffs fall from 27.5 percent to zero.

EU will reciprocate by cutting tariffs on 97.5 percent of India’s chemical exports from 12.8 percent to zero, a move expected to catalyze growth in bulk and specialty chemicals.  Indian pharmaceuticals already enjoy zero duty entry into the EU, but the deal would offer preferential access to the EU pharma market and improved competitiveness for medical devices.

The free flow of pharmaceutical, chemicals and machinery will help India to plug into global supply chain and offers Europe an alternative supply base and market.

The gains related to tariff reduction on chemicals are projected to concentrate in India’s industrial heartlands in the Bharuch–Vadodara cluster in Gujarat and Maharashtra’s chemical belt, boosting downstream manufacturing. An export surge is anticipated from Thane–Raigad, Bengaluru–Tumakuru, Hyderabad, and Visakhapatnam, supported by established clusters of suppliers and testing services.

Preferential FTA access to pharma strengthens India’s ability to expand in the EU’s large pharma market, while also improving the outlook for medical devices where competitiveness matters. The strongest export push is expected from Thane–Raigad in Maharashtra, Bengaluru–Tumakuru in Karnataka, Hyderabad in Telangana, and Visakhapatnam in Andhra Pradesh, supported by clusters of suppliers, packaging, testing and logistics services.

While European firms gain access to India's affluent urban patient base for high-value biologics, Indian generic manufacturers are eyeing the EU’s $2 billion market for biosimilars and complex generics.

Europe accounted for roughly 19-21 percent of India's pharmaceutical exports, estimated at approximately $5.8 billion in FY25, commerce ministry data shows. Generic drug formulations and biosimilars account for 75–80 percent of exports, followed by bulk drugs (APIs) and vaccines. EU primarily exports high-value patented drugs, biologics and specialised medical apparatus.

Indian industry relies on Europe for manufacturing and testing equipment, reagents, active pharmaceutical ingredients (APIs), and specialty solvents.

EU also clarified that all imports from India to the EU will continue to be subject to the EU's strict health and product safety rules, with no exception.

On the contentious intellectual property (IP) rights, EU said the agreement also provides a high level of protection and enforcement of IP rights, including with respect to copyright, trademarks, designs, protection of trade secrets and undisclosed information, plant varieties.

"The agreement foresees that each Party will have measures, procedures and remedies to ensure the enforcement of intellectual property rights," EU said.

The story will be updated, following the availability of finer details of the trade deal.